SIRS 2022 | Progress In Mind

Home

Progress in Mind reports from the Annual Schizophrenia International Research Society Conference (SIRS)

Once again, the Progress in Mind Resource Center is pleased to bring you highlights from the SIRS Congress. This year’s annual congress will be held in a hybrid meeting format allowing in-person attendance at the Firenze Fiera Fortezza da Basso in Florence, Italy or virtually on the SIRS Virtual Meeting Platform. This year’s theme is Moving Forward Together: Diversity in Global Research, and we strive to capture and bring you some of the latest research around schizophrenia as reported from this exciting Congress.

Read time: 2 min

Congress highlights

Inflammation and glutamate dysregulation: unravelling the aetiology of schizophrenia

Reduced glutamatergic signalling and immune dysregulation are two major aetiological hypotheses in...

Read time: 2 min

Congress highlights

Are prior mood disorders more important than positive symptoms for predicting psychosis?

Predicting which individuals will develop a psychotic disorder or transition from high risk of...

Read time: 3 min

Congress highlights

Improving treatment adherence in patients with early-phase schizophrenia

Early treatment engagement and a robust treatment response in patients with schizophrenia may be a...

Read time: 3 min

Congress highlights

Do early intervention services impact long-term outcomes in patients with psychosis?

Early intervention services (EIS) specifically designed to meet the needs of patients with early-...

Read time: 2 min

Congress highlights

Can we predict conversion to first-episode psychosis?

A better understanding of the pre-psychotic and prodromal symptoms of psychosis can aid correct...

Read time: 3 min

Congress highlights

Should we treat women with schizophrenia differently to men?

Gender is often not considered in the treatment of patients with schizophrenia. But women have...

Other conferences

Read time: Read time: 1 min

Read time: Read time: 1 min

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind MENA Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind Greece Continue to Progress in Mind South East Asia Continue to Progress in Mind Middle East & Africa Continue to Progress in Mind United Kingdom Continue to Progress in Mind Sweden Continue to Progress in Mind Norge Continue to Progress in Mind Denmark Continue to Progress in Mind Japan RC Continue to Progress in Mind България Continue to Progress in Mind Israel Continue to Progress in Mind Sweden Continue to Progress in Mind Finland Continue to Progress in Mind Ukraine Continue to Progress in Mind Belgium & Luxembourg Continue to Progress in Mind Switzerland Continue to Progress in Mind Germany Continue to Progress in Mind Austria

You are leaving Progress in Mind

Continue to

Cancel

Progress in Mind Belux

Accept Cancel

Login as a registered health care professional

Please enter your email to continue

Register as a health care professional

Please enter your email to continue

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intended for health care professionals.

All the information included in the Website is related to diseases, investigations and existing or potential treatment options and, therefore, directed to health professionals . The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country